Total: 2028

    Digitally enabled therapies for adults with anxiety disorders: early value assessment

    Six digitally enabled therapies can be used as treatment options for adults with anxiety disorders while further evidence is generated on their clinical and cost effectiveness, once they have appropriate approval. The following technologies can only be used once they have Digital Technology Assessment Cr...

    Digitally enabled therapies for adults with depression: early value assessment

    Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depressio...

    Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)

    J Bras Pneumol; 49 (2), 2023
    A fibrose cística (FC) é uma doença genética que resulta em disfunção da proteína reguladora de condutância transmembrana da FC (CFTR), que é um canal de cloro e bicarbonato expresso na porção apical de células epiteliais de diversos órgãos. A disfunção dessa proteína resulta em manifest...

    Saudi Critical Care Society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: reviewed for evidence-based integrity and endorsed by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine

    Ann Intensive Care; 13 (1), 2023
    To develop evidence-based clinical practice guidelines on venous thromboembolism (VTE) prevention in adults with trauma in inpatient settings. The Saudi Critical Care Society (SCCS) sponsored guidelines development and included 22 multidisciplinary panel members who completed conflict-of-interest forms. ...

    Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

    People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy). Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...

    Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing. Guidance development process Early value assessment (EVA) guidance rapidly provides recommendations on promising health technologies that have the potential to address national...